Standard BioTools (LAB) Projected to Post Quarterly Earnings on Monday

Key Points

• Standard BioTools is expected to release its Q2 2025 earnings on August 11th, with analysts forecasting earnings of ($0.04) per share and revenue of $39.83 million.
• AQR Capital Management LLC significantly increased its stake in Standard BioTools by 862.2% during the first quarter, owning 53.74% of the company’s stock after the acquisition.
• TD Cowen has upgraded Standard BioTools' shares to a "strong-buy" rating, indicating positive sentiment among analysts.

Standard BioTools (NASDAQ:LAB - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data after the market closes on Monday, August 11th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $39.83 million for the quarter.

Standard BioTools Stock Performance

NASDAQ LAB opened at $1.30 on Monday. Standard BioTools has a twelve month low of $0.92 and a twelve month high of $2.32. The stock has a market cap of $493.77 million, a price-to-earnings ratio of -3.71 and a beta of 1.32. The firm's 50 day moving average price is $1.21 and its two-hundred day moving average price is $1.22.

Hedge Funds Weigh In On Standard BioTools

An institutional investor recently raised its position in Standard BioTools stock. AQR Capital Management LLC grew its stake in shares of Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 862.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 482,912 shares of the company's stock after acquiring an additional 432,725 shares during the period. AQR Capital Management LLC owned 0.13% of Standard BioTools worth $522,000 as of its most recent SEC filing. Institutional investors and hedge funds own 53.74% of the company's stock.

Analysts Set New Price Targets

Separately, TD Cowen upgraded shares of Standard BioTools to a "strong-buy" rating in a research report on Thursday, July 17th.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.